The Advanced Research on Cancer Immunology
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccination Against Cancer and Chronic Diseases".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 85
Special Issue Editors
Interests: immuno oncology; drug discovery; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals
Interests: cancer immunology; cancer prevention; vaccines; clinical development
Special Issue Information
Dear Colleagues,
Cancer immunology has transformed oncology by unlocking new therapeutic avenues that mobilize the immune system to recognize and eliminate tumors. While approaches such as immune checkpoint inhibitors, adoptive cell transfer, monoclonal antibodies, and therapeutic cancer vaccines have achieved meaningful clinical successes, their effectiveness is often hindered by the immunosuppressive tumor microenvironment (TME). Tumors evade immune destruction through several mechanisms, including upregulation of checkpoint ligands, recruitment of regulatory T cells and myeloid-derived suppressor cells, and secretion of inhibitory cytokines. This chapter highlights current insights into how the TME orchestrates immune suppression, the resulting challenges for immunotherapy resistance, and emerging strategies aimed at overcoming these barriers. A deeper understanding of these processes will be critical for developing next-generation immunotherapies with greater efficacy and long-lasting patient benefit.
Dr. Pasupathi Sundaramoorthy
Dr. Naresh Poondla
Dr. Cody C. Mchale
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor microenvironment
- immunosuppression
- immune checkpoint inhibitors
- adoptive cell transfer
- cancer vaccines
- immunotherapy resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
